High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML. [electronic resource]
Producer: 20030407Description: 2152-5 p. digitalISSN:- 0006-4971
- Adult
- Aged
- Antigens, CD34 -- analysis
- Antineoplastic Agents -- therapeutic use
- Apoptosis -- genetics
- Benzamides
- Blast Crisis -- drug therapy
- Chemokines, CC -- genetics
- Drug Resistance, Neoplasm -- genetics
- Drug Screening Assays, Antitumor
- Female
- Gene Expression
- Humans
- Imatinib Mesylate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Middle Aged
- Piperazines -- therapeutic use
- Platelet Count
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins c-bcl-2
- Pyrimidines -- therapeutic use
- RNA, Messenger -- analysis
- Remission Induction
- Stem Cell Transplantation
- Transplantation, Homologous
- Tumor Cells, Cultured
- bcl-2-Associated X Protein
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.